J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
Potential For Post-Tagrisso Therapy Niche
Executive Summary
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
You may also be interested in...
Advanced Antibodies Will Revolutionize The Future Of IO
Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.
Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout
Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.
Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.